Rev Invest Clin
-
Transthyretin (TTR) amyloidosis (ATTR) is a progressive condition characterized by multiorgan accumulation of amyloid deposits composed of transthyretin (TTR) fibrils. Over the past decades, despite being a rare disease, ATTR amyloidosis has enabled top-tier therapeutics. In the 90s, organ transplantation was the mainstream therapeutic option and fostered distinct approaches, such as combined liver-heart transplant and domino (sequential) liver transplantation. ⋯ Over the past decade, oriented genetic therapies emerged to prevent, control, and, surprisingly, reverse amyloid deposition. Silencing the TTR gene using different strategies is flourishing, and ongoing trials continue to evaluate diverse approaches to optimize their application. The following perspective describes the currently available treatments for ATTR amyloidosis and the prospects on the potential application of these strategies in other medical fields.
-
In this article, a series of original manuscripts and reviews published between 2015 and 2021 in the Revista de Investigación Clínica -Clinical and Translational Investigation- chosen by the Editors are presented. The articles were selected according to what the editors considered are the most outstanding contributions based on originality, and the potential impact of the information provided on translational medicine, rather than on the number of readings and citations.
-
In recent decades, there has been an increase in the presence of metabolic disorders associated with obesity. Central in the treatment of these conditions, including abnormalities in glucose and lipid metabolism, dietary strategies play an important role. ⋯ The concept of personalized nutrition or precision nutrition has been recently developed, which states that diet is not the only factor accountable for metabolic responses such as postprandial glucose peaks, but that other factors are also involved, one of the most important of which is the gut microbiota. Therefore, the future of nutritional interventions is to generate algorithms based on the type of food consumed, biochemical parameters, physical activity, genetic variability, and especially the gut microbiota to predict the type of diet a person requires according to his or her metabolic alterations.
-
Since December 2019, when severe acute respiratory syndrome coronavirus 2 emerged in Wuhan, China, this virus and the resulting disease, coronavirus disease (COVID-19), has spread worldwide. What has occurred in this year and a half goes beyond anything we have dealt with, as humankind, in the past two centuries, perhaps obscured only by war. ⋯ Here, we aim to reflect on the basic structure of the virus and associate its behavior to that of determining factors of the human condition that may be modifiable soon. Needless to say, we find our effort clearly incomplete, and that both scientific and social aspects regarding COVID-19 or any other pandemic encountered in the future, will be constantly changing, from their beginning to their end.
-
Historical Article
MY YEARS AS COEDITOR OF THE REVISTA DE INVESTIGACIóN CLíNICA AND THE 1993-1998 READERS OF OUR JOURNAL.
Some information on our readers during my years as coeditor of the Revista de Investigación Clínica are presented on the basis that readers, unlike editors, have no conflict of interest in evaluating scientific publications. The information provided is restricted to the past 6 years (1993-1998) of my 11 years as coeditor since the number of reader visits to our on-line articles began in 1993. ⋯ These figures suggest that our journal became at the end of the 20th Century a valuable information source for physicians in Mexico. It was the original idea that led Salvador Zubirán to launch this journal in 1948.